CUREVAC N.V.
10,822.02
USD
(-1.33%)
03/28/2025 - 16:34
Closed 15 min delayed data - NASDAQ Stocks
| Open: | 10,965.93 |
| Change: | -146.34 |
| Volume: | 0 |
| Low: | 10,785.16 |
| High: | 10,965.93 |
| High / Low range: | 180.77 |
| Type: | Stocks |
| Ticker: | CVAC |
| ISIN: | NL0015436031 |
CUREVAC N.V. news, videos and press releases - Page 2
For more news please use our advanced search feature.
CUREVAC N.V. - More news...
CUREVAC N.V. - More news...
- 07/03/2024 - 02:40 CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
- 07/03/2024 - 02:40 GSK and CureVac to Restructure Collaboration into New Licensing Agreement
- 06/24/2024 - 20:05 EQS-News: CureVac Announces Voting Results of General Meeting
- 06/24/2024 - 16:20 CureVac Announces Voting Results of General Meeting
- 05/28/2024 - 11:00 EQS-News: CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
- 05/28/2024 - 07:20 CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
- 05/23/2024 - 11:00 EQS-News: CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
- 05/23/2024 - 07:20 CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
- 04/24/2024 - 11:06 EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
- 04/24/2024 - 11:03 EQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
- 04/24/2024 - 11:00 EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
- 04/24/2024 - 07:30 CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
- 04/24/2024 - 07:20 CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
- 04/24/2024 - 07:20 CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
- 04/18/2024 - 11:00 EQS-News: CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
- 04/18/2024 - 07:15 CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
- 04/16/2024 - 11:00 EQS-News: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
- 04/16/2024 - 07:15 CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
- 04/04/2024 - 11:00 EQS-News: CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
- 04/04/2024 - 07:15 CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
- 01/05/2024 - 12:00 EQS-News: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
- 01/05/2024 - 07:30 CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
- 12/19/2023 - 14:23 EQS-News: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
- 12/19/2023 - 09:35 CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
- 11/14/2023 - 12:00 EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
- 11/14/2023 - 07:30 CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
- 11/01/2023 - 12:00 EQS-News: CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
- 11/01/2023 - 08:15 CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
- 09/28/2023 - 11:00 EQS-News: CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
- 09/12/2023 - 11:00 EQS-News: CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
